

1 **Understanding the barriers to pooled SARS-CoV-2 testing in the United** 2 **States**

3

4 Eli P. Fenichel, Ph.D¹, Anna Gilbert, Ph.D^{2,3}, Gregg Gonsalves, Ph.D⁴, and Anne L. Wyllie,
5 Ph.D^{4*}

6

7 ¹ Yale School of the Environment, 195 Prospect St. New Haven, CT, 06511

8 ² Department of Mathematics, Yale University, 10 Hillhouse Avenue, New Haven, CT, 06511,

9 ³ Department of Statistics & Data Science, Yale University, 10 Hillhouse Avenue, New Haven, CT, 06511

10 ⁴ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St, New
11 Haven, CT 06510

12

13 Corresponding author: Anne Wyllie, anne.wyllie@yale.edu, 203-781-6942

14

15 Word count:1196

16

17 **Abstract**

18 Pooled testing for SARS-CoV-2 detection is instrumental for increasing test capacity while
19 decreasing test cost, key factors for sustainable, long-term surveillance measures. While
20 numerous pooled approaches have been described, uptake by labs has been limited. We
21 surveyed 90 US labs to understand the barriers to implementing pooled testing.

22

23

24

25 Early in the pandemic testing for SARS-CoV-2 emerged as an Achilles' heel of the United
26 States' national response (1). The failure to scale-up testing programs rapidly, delays in test
27 processing and return of results led to delays downstream in self-isolation, diagnosis and
28 treatment, undercounting of infections, fear and confusion. Proposals for novel strategies
29 involved pooling of samples from multiple individuals into one testing run. Many countries,
30 including Israel, Germany, South Korea and China, rapidly implemented pooling as part of
31 national plans. The US never implemented pooling as part of its own strategy in earnest (2).
32 According to Google Scholar, over 10,000 papers with key words "COVID" and "pooling" were
33 'published' in 2020. Pooling samples to increase throughput is not a new idea (3). For most
34 realistic test positive levels even simple pooling designs greatly increase capacity (4). So, why
35 has pooled testing been so rare in the US? To resolve this question, we explored the barriers
36 facing labs to expand testing capacity.

37
38 On December 9, 2020, we invited 362 labs that had contacted the Yale School of Public Health
39 expressing interest in implementing the SalviaDirect test (5), to participate in a survey to
40 evaluate testing constraints and pooling strategies for SARS-CoV-2 testing. The survey was
41 distributed using Qualtrics and three reminders were sent. The survey closed on January 21,
42 2021. Of the 93 responses received (25.7% response rate), 90 responses were from CLIA
43 certified labs conducting SARS-CoV-2 testing. The remaining three were excluded from the
44 analyses. Nearly half of the labs responding were for profit (n=42), followed by university
45 affiliated labs (n=9), with the remainder made up by community, non-profit, and government
46 laboratories. The respondent labs reported serving a variety of testing populations, the bulk
47 consisting of outpatient and community testing. While most conducted diagnostic testing, many
48 labs reported testing also for general surveillance and screening for specific events. The high
49 reporting of diagnostic testing, which is likely representative across all CLIA labs, is important in

50 the context of pooling, which differs from testing for screening and surveillance at the population
51 scale.

52
53 The survey included an open-ended question about the barriers to pooling. A major common
54 barrier to the implementation of pooling by labs was a lack of methods accepted by the
55 necessary authorities, including the FDA, CLIA regulations or their own laboratory directors.
56 Reports of a lack of clear protocols and guidance on the methodology for pooled testing
57 contributed to this. Many labs expressed that even if protocols were available, a lack of time and
58 resources limited their ability to validate these in-house, preventing proof-of-concept
59 implementation. Thus, demonstration of the effectiveness of pooling in their setting is lacking. In
60 that regard, numerous labs reported that local case-positivity rates were simply too high to
61 warrant pooling, despite recent lab-based data demonstrating the benefit of pooling five
62 samples up to a ~30% test positive rate (4). Throughout, there were a substantial number of
63 concerns about the effect of pooling on the sensitivity of detection and the increased risk for
64 false negative results due to sample dilution.

65
66 Operational and administrative barriers were also a common theme. Labs frequently reported
67 that reflex testing of the most common Dorfman approach (3), where samples from positive
68 pools are re-visited for individual re-testing, are too logistically difficult to manage or too
69 resource demanding. Labs viewed the need to re-visit samples of positive pools as disruptive to
70 the standard testing flow and staffing practices, expressing concerns that this would add to the
71 time of reporting out positive tests. A major concern was the additional logistics required for
72 following samples through the pooled testing process and the lack of the necessary software to
73 track samples through the workflow. Important to any testing program were concerns regarding
74 reimbursement and billing when samples are tested in pools as well as contract obligations.
75 Limited staff to dedicate to tackling these issues came up repeatedly.

76

77 Survey responses demonstrated that the SARS-CoV-2 testing environment in the US is highly
78 heterogeneous, particularly in regards to the supplies, testing platforms and the variety of
79 sample types received. While a majority of labs use 96-well PCR instruments, 384-well
80 instruments are also common, with some labs reporting non-standard plate sizes in upstream
81 processes. Many labs utilize multiple instruments in their testing procedures, which can vary in
82 the number of samples each can process. These inter-lab variations in testing workflows are
83 important for pooled testing strategies: a protocol developed for one lab may not be easily
84 translated into another. Those developing pooled testing strategies need to recognize that labs
85 are working with fixed physical and human capital constraints, and that new labs are not being
86 built around pooling strategies, such constraints cannot be assumed away.

87

88 Higher test throughput, lower costs per test, and faster turnaround times are all margins for
89 testing improvement. Increasing the number of samples per test in a pooling structure can be
90 part of that solution. Laboratories using an extraction process report that it takes on average 4.6
91 hours to test a sample from start to finish (extraction-less = 3.0 hours), but there is substantial
92 variation (Figure 1). The small number of labs (n=6) in our sample that engage in pooling
93 reported total testing time inline with these figures. On average samples wait in labs for 93
94 minutes prior to extraction-less workflows and 279 minutes prior to extraction-based tests. The
95 average time to set-up and run PCR is 94 minutes, with little difference between labs. For labs
96 performing full RNA extraction, this process takes on average 57 minutes. Reset or cycle times
97 between processes are on average 18 minutes for extraction and PCR. These times are one
98 motivation for laboratories focused on faster turn around to be wary of designs that require
99 retesting of samples, which can add hours to the process.

100

101 The need for testing will remain for the years to come. Pooled testing offers sustainable
102 surveillance measures that support long term programs, essential for the early detection of virus
103 resurgence or the emergence of variants of concern. While testing programs can be maintained
104 by pooled PCR testing, labs require guidance on how to transition from traditional diagnostic
105 testing to pooled surveillance. Importantly, our survey suggests that the major barriers to uptake
106 and implementation of pooled testing in the US may not simply be the number of tests a lab can
107 process per day, rather it is the lack of adequate resources guidance on clinical best practices
108 to transition to pooling. Additionally, a number of labs did not feel that pooled testing was
109 necessary given current testing capacity constraints at present. If the appropriate resources
110 were made available however, labs reported that even with current non-pooled testing
111 strategies, they could on average already increase testing capacity by 60%. While labs need to
112 see more evidence supporting the ability of pooled testing strategies to successfully move from
113 theory to a reliable and resource-savings laboratory practice, logistical solutions to support
114 implementation and general processing remain vital. Responses to our survey highlight the
115 importance of consulting end-users, those that solutions are being designed for, so challenges
116 can be crafted to meet the specific needs out in the field. It may be surprising to those designing
117 pooling strategies to learn that labs view pooling as more time consuming, delaying test
118 reporting.


119

120

121 **References**

- 122 1. Schneider EC. Failing the Test - The Tragic Data Gap Undermining the U.S. Pandemic
123 Response. *N Engl J Med*. 2020 Jul 23;383(4):299–302.
- 124 2. Wu KJ. Why Pooled Testing for the Coronavirus Isn't Working in America. *The New York*
125 *Times* [Internet]. 2020 Aug 18 [cited 2021 Feb 21]; Available from:
126 <https://www.nytimes.com/2020/08/18/health/coronavirus-pool-testing.html>

- 127 3. Dorfman R. The Detection of Defective Members of Large Populations. *Ann Math Stat.*
128 1943;14(4):436–40.
- 129 4. Watkins A, Fenichel E, Weinberger D, Vogels CBF, Brackney D, Casanovas-Massana A, et
130 al. Increasing SARS-CoV-2 Testing Capacity with Pooled Saliva Samples. *Emerging*
131 *Infectious Disease journal* [Internet]. 2021;27(4). Available from:
132 https://wwwnc.cdc.gov/eid/article/27/4/20-4200_article
- 133 5. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, et al. SalivaDirect:
134 A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity. *Med*
135 [Internet]. 2020 Dec 26; Available from:
136 <http://www.sciencedirect.com/science/article/pii/S2666634020300763>
137



138
139 **Figure 1.** The variation in timing constraints for critical steps of SARS-CoV-2 testing workflows
140 with or without RNA extraction.

141